epirubicin | 791005-82-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: epirubicin
• 英文别名: (7S,9S)-7-[(2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• CAS: 791005-82-8
• 化学式: C₂₇H₂₉NO₁₁
• 分子量: 543.527
• InChiKey: AOJJSUZBOXZQNB-WPFMFTOPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  206
• 氢给体数：
  6
• 氢受体数：
  12

文献信息

• PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE
  申请人：REMEGEN, LTD.

  公开号：US20200138968A1

  公开（公告）日：2020-05-07

  The present disclosure relates to a process for preparing an intermediate of antibody-drug conjugate. Compared with the conventional art, the process for preparing an intermediate of the antibody-drug conjugate provided by the present disclosure significantly reduces the feed loss for drug moiety, such as MMAD/MMAE or MMAF, etc., as drug moiety is involved in the last step of the reaction, thereby effectively reducing production costs, as well as increasing production efficiency. In addition, the process provided by the present disclosure is simple, environmentally friendly and suitable for large-scale industrialization.

  本公开涉及一种用于制备抗体-药物偶联物的中间体的方法。与现有技术相比，本公开提供的用于制备抗体-药物偶联物中间体的方法显著减少了药物部分的投料损失，例如MMAD/MMAE或MMAF等，因为药物部分参与反应的最后一步，从而有效降低生产成本，同时提高生产效率。另外，本公开提供的方法简单、环保，适合大规模工业化。
• ONE-POT PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY-DRUG CONJUGATE
  申请人：MABPLEX INTERNATIONAL, LTD.

  公开号：US20210085799A1

  公开（公告）日：2021-03-25

  The present invention relates to a “one-pot process” for preparing intermediate of antibody-drug conjugate. The preparation process provided by the present invention is simple in operation, and needs no such steps like concentration, washing and filtration of the intermediate reaction liquid, disposal of the organic waste liquid, and packaging and storage of the intermediate. The entire reaction system comprises only one separation and purification treatment, saving costs for labor, equipment, venues, raw materials, etc., and greatly reducing the pollution to the environment. In addition, the “one-pot process” for preparing intermediate of antibody-drug conjugate of the present invention produces the intermediate of antibody-drug conjugate with higher yield. The “one-pot process” for preparing intermediate of antibody-drug conjugate provided by the present invention is more suitable for scale-up production.

  本发明涉及一种用于制备抗体药物偶联物中间体的“一锅法”工艺。本发明提供的制备工艺操作简单，无需对中间体反应液进行浓缩、洗涤和过滤，处理有机废液，以及中间体的包装和储存等步骤。整个反应体系仅包含一次分离和纯化处理，节省了人力、设备、场地、原材料等成本，极大地减少了对环境的污染。另外，本发明的抗体药物偶联物中间体的“一锅法”工艺能够以更高的收率产生抗体药物偶联物中间体。本发明提供的抗体药物偶联物中间体的“一锅法”工艺更适合放大生产。
• Legumain Activated Doxorubicin Derivative as well as Preparation Method and Application Thereof
  申请人：Yafei (Shanghai) Biopharmaceutical Co., Ltd.

  公开号：US20190135858A1

  公开（公告）日：2019-05-09

  The present invention discloses doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R 3 in compound B is Leu or absent; R 4 is any one amino acid selected from the group consisting of Ala and Thr; R 5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R 6 is wherein n=1-20; or wherein R 7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.

  本发明揭示了靶向Legumain激活的阿霉素衍生物，其制备方法和用途。阿霉素衍生物是通过化合物A的氨基与化合物B的羧基之间的缩合得到的，具有以下结构：化合物A和B分别具有以下结构：其中，化合物B中的R3是Leu或不存在；R4是从Ala和Thr组成的氨基酸中选择的任一种；R5是从Ala、Thr和Asn组成的氨基酸中选择的任一种；R6是其中n=1-20；或其中R7是取代或未取代的、直链或支链的、饱和或不饱和的C1-C20脂肪烃，或取代或未取代的C6-C20芳香烃。本发明的阿霉素衍生物具有针对肿瘤的特异性靶向性，并且与阿霉素相比具有较长的体内代谢半衰期。它们表现出高效且安全的抗肿瘤效果，并可用于制备抗肿瘤药物。
• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• US9982011B2
  申请人：——

  公开号：US9982011B2

  公开（公告）日：2018-05-29